MetaCap

Erasca Inc. (ERAS)

NASDAQ: ERASHealth CareBiotechnology: Pharmaceutical PreparationsUSD

14.12-0.18 (-1.26%)

At close: Oct 7, 4:00 PM ET · Delayed 15 min

After hours: 14.12 0.00%

ERAS stock chart

Technical analysis

Key statistics

All statistics
Market cap
$4.94B
P/E (TTM)
—
Forward P/E
—
EPS (TTM)
-$0.95
Dividend yield
None
Ex-dividend date
—
52-week range
2.11 – 24.28
Day range
13.93 – 14.57
Volume / Avg
3.83M / 4.32M
Beta
—
Shares outstanding
349.76M
Next earnings
Nov 11, 2026

52-week range

$2.11$24.28

ERAS stock today

Shares of Erasca (ERAS) finished lower on Oct 7 at $14.12, a drop of 1.26% or $0.18 per share, versus the S&P 500's 0.22% decline. Shares are 41.8% below their 52-week high of $24.28, set on Apr 23, 2026 and 570.8% above the 52-week low of $2.11, in the middle of the past year's range. ERAS is up 280.4% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 470.6%.

Erasca has posted a net loss over the last twelve months (EPS of -$0.95), so its P/E ratio is not meaningful. Erasca's next earnings report is expected on Nov 11, 2026.

Summary generated from market data by MetaCap's automated system. Methodology

About Erasca

Company profile

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc.

Sector
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Jonathan E. Lim M.D.
Headquarters
San Diego, CA
Employees
103
IPO year
2021
Website
erasca.com

Financial highlights

Full financials

Erasca reported a net loss of $124.5 million, compared with a loss of $161.7 million a year earlier. Diluted earnings per share came in at -$0.44.

Erasca annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-124.55M$-161.65M$-125.04M$-242.81M$-122.76M
EPS (diluted)$-0.44$-0.69$-0.83$-1.99$-1.85

Analyst forecast

Forecast

Consensus (9 analysts)

none

Avg. price target

$24.11+70.75%

  • Strong buy 2
  • Buy 5
  • Hold 2
  • Sell 0
  • Strong sell 0

Target range

Low $20.00High $33.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Next report
Nov 11, 2026
Last reported (Q2 2026)
Aug 11, 2026
EPS actual vs est.
$-0.14 vs —

ERAS news

All ERAS news

Erasca peers

Health Care sector
ERAS peer companies
CompanyPrice% ChgMarket capCompare
TVTXTravere Therapeutics Inc.53.44-4.54%$5.04Bvs ERAS
GRFSGrifols S.A. ADR7.50-0.27%$5.10Bvs ERAS
COGTCogent Biosciences Inc.30.14-0.79%$5.23Bvs ERAS
MIRMMirum Pharmaceuticals Inc.80.64+1.75%$5.24Bvs ERAS
DNTHDianthus Therapeutics Inc.84.88-0.61%$4.75Bvs ERAS
PTCTPTC Therapeutics Inc.63.23-0.74%$5.28Bvs ERAS
MANEVeradermics Incorporated110.95+1.83%$4.64Bvs ERAS
EWTXEdgewise Therapeutics Inc.39.57-1.12%$4.30Bvs ERAS

Indexes, lists and sector

Erasca stock FAQ

What is Erasca's stock price today?

ERAS last traded at $14.12 as of Oct 7, 4:00 PM EDT, down 1.26% on the day. Prices are delayed at least 15 minutes.

When is Erasca's next earnings date?

Erasca is expected to report earnings on Wednesday, November 11, 2026.

Who is Erasca's CEO?

Dr. Jonathan E. Lim M.D. is the chief executive officer of Erasca Inc., which has about 103 employees.

What is the ERAS 52-week high?

The 52-week high for ERAS is $24.28 and the 52-week low is $2.11. The stock is currently 41.8% below its high.

Compare ERAS